These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16570285)

  • 1. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder.
    van Oers JM; Adam C; Denzinger S; Stoehr R; Bertz S; Zaak D; Stief C; Hofstaedter F; Zwarthoff EC; van der Kwast TH; Knuechel R; Hartmann A
    Int J Cancer; 2006 Sep; 119(5):1212-5. PubMed ID: 16570285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses.
    Obermann EC; Junker K; Stoehr R; Dietmaier W; Zaak D; Schubert J; Hofstaedter F; Knuechel R; Hartmann A
    J Pathol; 2003 Jan; 199(1):50-7. PubMed ID: 12474226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
    Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
    Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma.
    Hartmann A; Moser K; Kriegmair M; Hofstetter A; Hofstaedter F; Knuechel R
    Am J Pathol; 1999 Mar; 154(3):721-7. PubMed ID: 10079249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer.
    Stoehr R; Zietz S; Burger M; Filbeck T; Denzinger S; Obermann EC; Hammerschmied C; Wieland WF; Knuechel R; Hartmann A
    Eur Urol; 2005 Jan; 47(1):58-63. PubMed ID: 15582250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
    Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
    Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
    Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder.
    Hartmann A; Schlake G; Zaak D; Hungerhuber E; Hofstetter A; Hofstaedter F; Knuechel R
    Cancer Res; 2002 Feb; 62(3):809-18. PubMed ID: 11830537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder.
    Cheng L; Lopez-Beltran A; Wang M; Whaley RD; De Souza A; Au S; Ge R; Cimadamore A; Amin A; Golijanin B; MacLennan GT; Osunkoya AO; Montironi R; Zhang S
    Mod Pathol; 2023 Jul; 36(7):100151. PubMed ID: 36906071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.
    Lindgren D; Liedberg F; Andersson A; Chebil G; Gudjonsson S; Borg A; Månsson W; Fioretos T; Höglund M
    Oncogene; 2006 Apr; 25(18):2685-96. PubMed ID: 16532037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.
    Simoneau AR; Spruck CH; Gonzalez-Zulueta M; Gonzalgo ML; Chan MF; Tsai YC; Dean M; Steven K; Horn T; Jones PA
    Cancer Res; 1996 Nov; 56(21):5039-43. PubMed ID: 8895761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
    López-Knowles E; Hernández S; Malats N; Kogevinas M; Lloreta J; Carrato A; Tardón A; Serra C; Real FX
    Cancer Res; 2006 Aug; 66(15):7401-4. PubMed ID: 16885334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
    Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
    J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.
    Smal MP; Rolevich AI; Polyakov SL; Krasny SA; Goncharova RI
    Exp Oncol; 2014 Dec; 36(4):246-51. PubMed ID: 25537218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development.
    Zieger K; Marcussen N; Borre M; Ørntoft TF; Dyrskjøt L
    Int J Cancer; 2009 Nov; 125(9):2095-103. PubMed ID: 19637316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer.
    Chow NH; Cairns P; Eisenberger CF; Schoenberg MP; Taylor DC; Epstein JI; Sidransky D
    Int J Cancer; 2000 Nov; 89(6):514-8. PubMed ID: 11102896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer.
    Stoehr R; Wissmann C; Suzuki H; Knuechel R; Krieg RC; Klopocki E; Dahl E; Wild P; Blaszyk H; Sauter G; Simon R; Schmitt R; Zaak D; Hofstaedter F; Rosenthal A; Baylin SB; Pilarsky C; Hartmann A
    Lab Invest; 2004 Apr; 84(4):465-78. PubMed ID: 14968126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation of FGFR3 mutations and chromosomal alterations in bladder cancer].
    Junker K; van Oers JM; Zwarthoff EC; Kania I; Schubert J; Hartmann A
    Verh Dtsch Ges Pathol; 2006; 90():151-8. PubMed ID: 17867592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.